Document Detail

Principal findings from a multicenter trial investigating the safety of follicular-fluid meiosis-activating sterol for in vitro maturation of human cumulus-enclosed oocytes.
MedLine Citation:
PMID:  17198705     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the safety of applying follicular-fluid meiosis-activating sterol (FF-MAS) in vitro to immature human oocytes. DESIGN: Phase I bicenter, randomized, parallel-group, controlled, partially blinded trial. SETTING: Third-level referral academic centers, including reproductive biology and genetics laboratories. PATIENTS: Endocrinologically normal women with a medical indication for IVF or intracytoplasmic sperm injection, or healthy volunteers. INTERVENTION(S): Subjects were randomized at a ratio 1 to 6 into either conventional GnRH-agonist and recombinant FSH stimulation (IVO) for oocyte retrieval, or minimally stimulated in vitro maturation (IVM) with the use of recombinant FSH. Retrieved immature oocyte cumulus complexes were cultured for 30 or 36 hours in one of six IVM culture conditions containing FF-MAS (range, 0.1-20 microM). Polar body-extruded oocytes from the IVO and IVM groups were processed for chromosomal analysis. MAIN OUTCOME MEASURE(S): The primary endpoint was the incidence of metaphase II stage oocytes with numeric chromosomal abnormalities, using full (spectral karyotyping) or partial (fluorescent in situ hybridization with seven probes) karyotyping or Giemsa count. A secondary objective was to document the frequency of metaphase II oocytes after IVM with FF-MAS supplements. RESULT(S): Oocyte cumulus complexes obtained from the IVO (mean, 8.9) and IVM (mean, 6.2) groups had equal maturation rates. Compared to IVO, exposure of germinal-vesicle oocytes for a maturation period of 30 hours did not increase aneuploidy. An exposure period of 36 hours doubled the aneuploidy rate, but this was significant only for the 20-muM dose of FF-MAS. CONCLUSION: Inclusion of 1-10 microM FF-MAS in a 30-hour IVM protocol is safe.
Johan Smitz; Helen-Mary Picton; Peter Platteau; Anthony Rutherford; Rita Cortvrindt; Julie Clyde; Daniela Nogueira; Paul Devroey; Karsten Lyby; Christian Gröndahl
Related Documents :
1697035 - Use of a hpaii-polymerase chain reaction assay to study dna methylation in the pgk-1 cp...
12416655 - Resumption of meiosis-i tissue to enucleated preovulatory oocytes: a preliminary report.
11768805 - Splitting and biopsy for bovine embryo sexing under field conditions.
12210115 - Pentadactyl ground state of the avian wing.
10987075 - Titin as a chromosomal protein.
1832505 - The emerging kinesin family of microtubule motor proteins.
Publication Detail:
Type:  Clinical Trial, Phase I; In Vitro; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2007-01-02
Journal Detail:
Title:  Fertility and sterility     Volume:  87     ISSN:  1556-5653     ISO Abbreviation:  Fertil. Steril.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-13     Completed Date:  2007-05-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  United States    
Other Details:
Languages:  eng     Pagination:  949-64     Citation Subset:  IM    
Center for Reproductive Medicine, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholestenes / adverse effects*
Chromosome Aberrations
Fertilization in Vitro
Follicle Stimulating Hormone
Oocytes / drug effects*,  physiology,  ultrastructure
Sperm Injections, Intracytoplasmic
Reg. No./Substance:
0/Cholestenes; 64284-64-6/4,4-dimethylcholesta-8,14,24-trienol; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transient ischemia increases neuronal nitric oxide synthase, argininosuccinate synthetase and argini...
Next Document:  Stent expansion in curved vessel and their interactions: a finite element analysis.